• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2004 - 2009年美国垂体肿瘤的描述性流行病学

Descriptive epidemiology of pituitary tumors in the United States, 2004-2009.

作者信息

Gittleman Haley, Ostrom Quinn T, Farah Paul D, Ondracek Annie, Chen Yanwen, Wolinsky Yingli, Kruchko Carol, Singer Justin, Kshettry Varun R, Laws Edward R, Sloan Andrew E, Selman Warren R, Barnholtz-Sloan Jill S

机构信息

Brain Tumor and Neuro-Oncology Center, Department of Neurosurgery, University Hospitals Case Medical Center;

出版信息

J Neurosurg. 2014 Sep;121(3):527-35. doi: 10.3171/2014.5.JNS131819. Epub 2014 Jun 13.

DOI:10.3171/2014.5.JNS131819
PMID:24926650
Abstract

OBJECT

Pituitary tumors are abnormal growths that develop in the pituitary gland. The Central Brain Tumor Registry of the United States (CBTRUS) contains the largest aggregation of population-based data on the incidence of primary CNS tumors in the US. These data were used to determine the incidence of tumors of the pituitary and associated trends between 2004 and 2009.

METHODS

Using incidence data from 49 population-based state cancer registries, 2004-2009, age-adjusted incidence rates per 100,000 population for pituitary tumors with ICD-O-3 (International Classification of Diseases for Oncology, Third Edition) histology codes 8040, 8140, 8146, 8246, 8260, 8270, 8271, 8272, 8280, 8281, 8290, 8300, 8310, 8323, 9492 (site C75.1 only), and 9582 were calculated overall and by patient sex, race, Hispanic ethnicity, and age at diagnosis. Corresponding annual percent change (APC) scores and 95% confidence intervals were also calculated using Joinpoint to characterize trends in incidence rates over time. Diagnostic confirmation by subregion of the US was also examined. The overall annual incidence rate increased from 2.52 (95% CI 2.46-2.58) in 2004 to 3.13 (95% CI 3.07-3.20) in 2009. Associated time trend yielded an APC of 4.25% (95% CI 2.91%-5.61%). When stratifying by patient sex, the annual incidence rate increased from 2.42 (95% CI 2.33-2.50) to 2.94 (95% CI 2.85-3.03) in men and 2.70 (95% CI 2.62-2.79) to 3.40 (95% CI 3.31-3.49) in women, with APCs of 4.35% (95% CI 3.21%-5.51%) and 4.34% (95% CI 2.23%-6.49%), respectively. When stratifying by race, the annual incidence rate increased from 2.31 (95% CI 2.25-2.37) to 2.81 (95% CI 2.74-2.88) in whites, 3.99 (95% CI 3.77-4.23) to 5.31 (95% CI 5.06-5.56) in blacks, 1.77 (95% CI 1.26-2.42) to 2.52 (95% CI 1.96-3.19) in American Indians or Alaska Natives, and 1.86 (95% CI 1.62-2.13) to 2.03 (95% CI 1.80-2.28) in Asians or Pacific Islanders, with APCs of 3.91% (95% CI 2.88%-4.95%), 5.25% (95% CI 3.19%-7.36%), 5.31% (95% CI -0.11% to 11.03%), and 2.40% (95% CI -3.20% to 8.31%), respectively. When stratifying by Hispanic ethnicity, the annual incidence rate increased from 2.46 (95% CI 2.40-2.52) to 3.03 (95% CI 2.97-3.10) in non-Hispanics and 3.12 (95% CI 2.91-3.34) to 4.01 (95% CI 3.80-4.24) in Hispanics, with APCs of 4.15% (95% CI 2.67%-5.65%) and 5.01% (95% CI 4.42%-5.60%), respectively. When stratifying by age at diagnosis, the incidence of pituitary tumor was highest for those 65-74 years old and lowest for those 15-24 years old, with corresponding overall age-adjusted incidence rates of 6.39 (95% CI 6.24-6.54) and 1.56 (95% CI 1.51-1.61), respectively.

CONCLUSIONS

In this large patient cohort, the incidence of pituitary tumors reported between 2004 and 2009 was found to increase. Possible explanations for this increase include changes in documentation, changes in the diagnosis and registration of these tumors, improved diagnostics, improved data collection, increased awareness of pituitary diseases among physicians and the public, longer life expectancies, and/or an actual increase in the incidence of these tumors in the US population.

摘要

目的

垂体瘤是发生于垂体的异常生长物。美国中枢脑肿瘤登记处(CBTRUS)收集了美国基于人群的原发性中枢神经系统肿瘤发病率的最大规模汇总数据。这些数据用于确定2004年至2009年期间垂体瘤的发病率及相关趋势。

方法

利用49个基于人群的州癌症登记处2004 - 2009年的发病率数据,计算具有ICD - O - 3(国际肿瘤疾病分类第三版)组织学编码8040、8140、8146、8246、8260、8270、8271、8272、8280、8281、8290、8300、8310、8323、9492(仅部位C75.1)和9582的垂体瘤每10万人口的年龄调整发病率,总体以及按患者性别、种族、西班牙裔身份和诊断时年龄进行计算。还使用Joinpoint计算了相应的年度百分比变化(APC)分数和95%置信区间,以描述发病率随时间的趋势。还检查了美国各分区的诊断确认情况。总体年发病率从2004年的2.52(95%CI 2.46 - 2.58)增至2009年的3.13(95%CI 3.07 - 3.20)。相关时间趋势得出的APC为4.25%(95%CI 2.91% - 5.61%)。按患者性别分层时,男性年发病率从2.42(95%CI 2.33 - 2.50)增至2.94(95%CI 2.85 - 3.03),女性从2.70(95%CI 2.62 - 2.79)增至3.40(95%CI 3.31 - 3.49),APC分别为4.35%(95%CI 3.21% - 5.51%)和4.34%(95%CI 2.23% - 6.49%)。按种族分层时,白人年发病率从2.31(95%CI 2.25 - 2.37)增至2.81(95%CI 2.74 - 2.88),黑人从3.99(95%CI 3.77 - 4.23)增至5.31(95%CI 5.06 - 5.56),美洲印第安人或阿拉斯加原住民从1.77(95%CI 1.26 - 2.42)增至2.52(95%CI 1.96 - 3.19),亚洲人或太平洋岛民从1.86(95%CI 1.62 - 2.13)增至2.03(95%CI 1.80 - 2.28),APC分别为3.91%(95%CI 2.88% - 4.95%)、5.25%(95%CI 3.19% - 7.36%)、5.31%(95%CI - 0.11%至11.03%)和2.40%(95%CI - 3.20%至8.31%)。按西班牙裔身份分层时,非西班牙裔年发病率从2.46(95%CI 2.40 - 2.52)增至3.03(95%CI 2.97 - 3.10),西班牙裔从3.12(95%CI 2.91 - 3.34)增至4.01(95%CI 3.80 - 4.24),APC分别为4.15%(95%CI 2.67% - 5.65%)和5.01%(95%CI 4.42% - 5.60%)。按诊断时年龄分层时,垂体瘤发病率在65 - 74岁人群中最高,在15 - 24岁人群中最低,相应的总体年龄调整发病率分别为6.39(95%CI 6.24 - 6.54)和1.56(95%CI 1.51 - 1.61)。

结论

在这个大型患者队列中,发现2004年至2009年期间报告的垂体瘤发病率有所增加。这种增加的可能解释包括记录的变化、这些肿瘤诊断和登记的变化、诊断方法的改进、数据收集的改善、医生和公众对垂体疾病认识的提高、预期寿命延长,以及/或者美国人群中这些肿瘤的实际发病率增加。

相似文献

1
Descriptive epidemiology of pituitary tumors in the United States, 2004-2009.2004 - 2009年美国垂体肿瘤的描述性流行病学
J Neurosurg. 2014 Sep;121(3):527-35. doi: 10.3171/2014.5.JNS131819. Epub 2014 Jun 13.
2
Descriptive Epidemiology of Spinal Meningiomas in the United States.美国脊髓膜瘤的描述性流行病学
Spine (Phila Pa 1976). 2015 Aug 1;40(15):E886-9. doi: 10.1097/BRS.0000000000000974.
3
Italian cancer figures, report 2012: Cancer in children and adolescents.《2012年意大利癌症数据报告:儿童和青少年癌症》
Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225.
4
Colorectal cancer incidence in the United States, 1999-2004 : an updated analysis of data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program.1999 - 2004年美国结直肠癌发病率:来自国家癌症登记计划和监测、流行病学及最终结果计划数据的更新分析
Cancer. 2009 May 1;115(9):1967-76. doi: 10.1002/cncr.24216.
5
Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: a population-based study.儿童、青少年和青年人群中分化型甲状腺癌发病率的增加:一项基于人群的研究。
J Pediatr. 2014 Jun;164(6):1481-5. doi: 10.1016/j.jpeds.2014.01.059. Epub 2014 Mar 12.
6
Incidence of vestibular schwannomas in the United States.美国前庭神经鞘瘤的发病率。
J Neurooncol. 2015 Sep;124(2):223-8. doi: 10.1007/s11060-015-1827-9. Epub 2015 May 30.
7
The descriptive epidemiology of craniopharyngioma.颅咽管瘤的描述性流行病学。
J Neurosurg. 1998 Oct;89(4):547-51. doi: 10.3171/jns.1998.89.4.0547.
8
Childhood cancer among Alaska Natives.阿拉斯加原住民中的儿童癌症。
Pediatrics. 2003 Nov;112(5):e396. doi: 10.1542/peds.112.5.e396.
9
Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994.原发性脑和中枢神经系统肿瘤的描述性流行病学:来自美国中枢脑肿瘤登记处的结果,1990 - 1994年
Neuro Oncol. 1999 Jan;1(1):14-25. doi: 10.1093/neuonc/1.1.14.
10
The epidemiology of central and extraventricular neurocytoma in the United States between 2006 and 2014.2006 年至 2014 年美国中枢和脑室外神经细胞瘤的流行病学。
J Neurooncol. 2019 May;143(1):123-127. doi: 10.1007/s11060-019-03144-9. Epub 2019 Mar 11.

引用本文的文献

1
Orthotopic pituitary tumors generated by stereotaxic GC cell injection in immunocompetent rats.在具有免疫活性的大鼠中,通过立体定向注射GC细胞产生的原位垂体肿瘤。
Acta Neuropathol Commun. 2025 Jul 5;13(1):149. doi: 10.1186/s40478-025-02052-6.
2
Endoscopic endonasal approaches for resection of suprasellar pituitary neuroendocrine tumors: a novel classification based on the optic chiasm and operative nuances.经鼻内镜入路切除鞍上垂体神经内分泌肿瘤:基于视交叉和手术细节的新分类
BMC Surg. 2025 Jul 3;25(1):254. doi: 10.1186/s12893-025-03001-9.
3
Surgical Treatment of Cushing's Disease: The Lessons Learned.
库欣病的外科治疗:经验教训
Adv Tech Stand Neurosurg. 2025;55:47-73. doi: 10.1007/978-3-031-90762-3_3.
4
Atherosclerosis enhances the efficacy of liposome-encapsulated bromocriptine in reducing the incidence of prolactinemia in pituitary tumors.动脉粥样硬化增强了脂质体包裹的溴隐亭在降低垂体瘤患者高催乳素血症发生率方面的疗效。
J Nanobiotechnology. 2025 May 29;23(1):392. doi: 10.1186/s12951-025-03465-0.
5
A Consensus for Pituitary Adenoma Diagnosis in Indonesia.印度尼西亚垂体腺瘤诊断共识
J ASEAN Fed Endocr Soc. 2025 May;40(1):8-13. doi: 10.15605/jafes.040.01.03. Epub 2025 Apr 29.
6
The impact of pituitary adenomas on cognitive performance: a systematic review.垂体腺瘤对认知功能的影响:一项系统综述。
Front Endocrinol (Lausanne). 2025 Apr 30;16:1534635. doi: 10.3389/fendo.2025.1534635. eCollection 2025.
7
Psychological burden in patients with sellar masses under conservative and surgical management.鞍区肿物患者在保守治疗和手术治疗下的心理负担
Neurosurg Rev. 2025 Jan 30;48(1):104. doi: 10.1007/s10143-025-03240-7.
8
The associations between risk factors and pituitary neuroendocrine tumors: A bidirectional Mendelian randomization study.风险因素与垂体神经内分泌肿瘤之间的关联:一项双向孟德尔随机化研究。
Medicine (Baltimore). 2024 Nov 22;103(47):e40617. doi: 10.1097/MD.0000000000040617.
9
Postoperative Hemorrhage and Venous Thromboembolism in Patients with Pituitary Adenomas Under Acetylsalicylic Acid.垂体腺瘤患者服用乙酰水杨酸后的术后出血和静脉血栓栓塞
J Clin Med. 2024 Nov 21;13(23):7020. doi: 10.3390/jcm13237020.
10
The rate of postoperative hematoma following risk-adapted cessation of oral anticoagulation in patients undergoing endoscopic endonasal surgery for pituitary adenomas.垂体腺瘤经鼻内镜手术患者中,根据风险调整停用口服抗凝药后的术后血肿发生率。
Acta Neurochir (Wien). 2024 Dec 6;166(1):496. doi: 10.1007/s00701-024-06387-2.